CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
11.86
0%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.09
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 11.86
Open 11.91
1-Year Change 21.65%
Day's Range 11.83 - 12.07
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 19, 2024 11.86 -0.13 -1.08% 11.99 12.07 11.79
Sep 18, 2024 11.86 0.10 0.85% 11.76 11.97 11.65
Sep 17, 2024 11.77 0.02 0.17% 11.75 11.78 11.63
Sep 16, 2024 11.76 0.05 0.43% 11.71 11.77 11.51
Sep 13, 2024 11.63 -0.11 -0.94% 11.74 11.89 11.58
Sep 12, 2024 11.71 0.38 3.35% 11.33 11.72 11.31
Sep 11, 2024 11.30 0.25 2.26% 11.05 11.36 10.95
Sep 10, 2024 11.12 0.00 0.00% 11.12 11.14 10.80
Sep 9, 2024 11.07 -0.16 -1.42% 11.23 11.43 11.06
Sep 6, 2024 11.22 -0.45 -3.86% 11.67 11.73 11.11
Sep 5, 2024 11.62 -0.15 -1.27% 11.77 11.85 11.60
Sep 4, 2024 11.73 -0.13 -1.10% 11.86 11.86 11.68
Sep 3, 2024 11.84 -0.03 -0.25% 11.87 11.95 11.80
Aug 30, 2024 12.05 0.15 1.26% 11.90 12.05 11.89
Aug 29, 2024 11.85 -0.03 -0.25% 11.88 11.91 11.74
Aug 28, 2024 11.86 0.22 1.89% 11.64 11.88 11.61
Aug 27, 2024 11.65 0.01 0.09% 11.64 11.71 11.57
Aug 26, 2024 11.71 -0.01 -0.09% 11.72 11.81 11.66
Aug 23, 2024 11.71 0.15 1.30% 11.56 11.73 11.54
Aug 22, 2024 11.66 -0.05 -0.43% 11.71 11.77 11.61

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Viatris Inc. Company profile

Viatris (VTRS) is a global healthcare company. It was formed in 2020 through the merger of Pfizer’s (PFE) off-patent branded and generic medicines division Upjohn and pharmaceutical firm Mylan. 

The merger of Mylan and Upjohn was announced in July 2019 and received final regulatory clearance in October 2020. Pfizer shareholders own 57% of Viatris and Mylan shareholders own 43%, according to the merger announcement. Viatris started trading on the Nasdaq Stock Exchange under the ticker VTRS in November 2020. 

Viatris is headquartered in Canonsburg, Pittsburgh, US. The company is operational in over 165 countries and has global centres in Shanghai, China and Hyderabad, India. 

Viatris operates about 40 manufacturing sites which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. The firm also produces numerous complex generics, biosimilars and global key brands.

Viatris offers treatment options across more than 10 major therapeutic areas covering a wide variety of non-communicable and infectious diseases. According to the company’s website, 50% of its total active pharmaceutical ingredient (API) capacity is devoted to antiretroviral (ARV), which is used against HIV infection. 

Some of the well-known and key brands under Viatris are anxiety treatment drug Xanax, antidepressant Zoloft, anti-inflammatory drug Celebrex and erectile dysfunction therapy Viagra, among others. Viatris also offers global biosimilars franchises focused on the areas of oncology, immunology, endocrinology, ophthalmology and dermatology.

Industry: Pharmaceuticals (NEC)

1000 Mylan Boulevard
CANONSBURG
PENNSYLVANIA 15317
US

News

BoE Preview: no change expected but forward guidance will be key

The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.

14:53, 19 September 2024

FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion

Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.

11:30, 19 September 2024

Bank of Japan Preview

The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.

09:40, 17 September 2024

FOMC Decision Preview

As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.

09:48, 16 September 2024

ECB Preview: cuts expected but the pace is uncertain

Markets expect the ECB to cut rates again in September, but how many more?

12:34, 11 September 2024

Market analysis: US CPI and PPI

Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.

07:56, 10 September 2024

Introducing Newsquawk: your new in-platform newsfeed

We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.

14:09, 20 August 2024

People also watch

XRP/USD

0.60 Price
-0.110% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

63,896.25 Price
+1.240% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,593.17 Price
+0.230% 1D Chg, %
Long position overnight fee -0.0181%
Short position overnight fee 0.0099%
Overnight fee time 21:00 (UTC)
Spread 0.30

Oil - Crude

70.94 Price
-0.290% 1D Chg, %
Long position overnight fee 0.0292%
Short position overnight fee -0.0511%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 640,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading